As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

QuantumCell received worldwide rights to NeuroRestore/ACD856, with closing contingent on foreign direct investment approvals in Sweden and Denmark under customary regulatory conditions. Financial ...

Introduction Depression and anxiety are significantly elevated among undergraduate university students worldwide. Despite this, treatment rates among this population remain low. To address this gap, ...

Financing will accelerate the development of HMNC’s neurosciences portfolio, including Phase 3-readiness activities for Ketabon (KET01) and ...

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million ...

Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United ...

VANCOUVER, BC, June 2, 2026 /CNW/ - via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated ...